Treatment efficacy and patient satisfaction of ustekinumab compared with tumor necrosis factor-alpha inhibitors in Chinese patients with moderate-to-severe psoriasis: a real-world study
Chinese moderate-to-severe psoriasis patients treated with ustekinumab have a better treatment response at 6 months with improved quality of life and patient satisfaction after 3-6 months of treatment when compared to TNFi.
Authors
- Xiaobo Jin
- Bing Xu (ORCID: https://orcid.org/0000-0002-7271-4438)
- Yanfeng Zhang (ORCID: https://orcid.org/0009-0002-3724-284X)
- Tao Yang (ORCID: https://orcid.org/0000-0001-6375-3622)
- Bin Guo (ORCID: https://orcid.org/0000-0003-0693-9695)
- Leiqiang Fan
Institutions
- Chengde Medical University (CN)
Publication Details
- Journal
- Journal of Dermatological Treatment
- Published
- 2024-09-19
- DOI
- https://doi.org/10.1080/09546634.2024.2405554
- Citations
- 4
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.96